MY ACCOUNT | NEWSLETTER |

Effects of subcutaneous buprenorphine injections in New Zealand white rabbits


Buprenorphine is a common analgesic administered to rabbits and high concentration formulations can reduce handling stress without sacrificing pain relief. The objective of this study was to evaluate the pharmacokinetics of high concentration buprenorphine and its metabolites following multiple subcutaneous doses in the rabbit. Laboratory variables (complete blood cell count, biochemistry profile, urinalysis) were compared for drug effects and injection sites were evaluated via histopathology.

The research team administered high concentration buprenorphine subcutaneously to six, 17-week-old, intact female, New Zealand white rabbits for three doses, 24 hours apart. Two control animals received an equal volume of saline. 

Blood samples were collected at multiple time intervals. Buprenorphine and its metabolites were measured via liquid chromatography-electrospray ionization-tandem mass spectrometry. Blood and urine profiles were collected prior to and following HCB administration and compared within and between groups. Injection sites and major organ systems were evaluated grossly and microscopically for drug effects.

High concentration buprenorphine administered once every 24 hours for three doses had a variable accumulation index of 1.68, reflecting variability in terminal half-life. Subsequently, the metabolites buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide had accumulation indices of 1.79 and 1.84, respectively. No significant laboratory changes were attributed to multiple dose drug administration. Local subcutaneous vasculitis and panniculitis were reported in rabbits receiving HCB. Ante-mortem examination did not find clinical disease, however 6 of 8 rabbits, including controls, had multifocal inflammatory changes in the liver and lungs on histopathology.

In conclusion, subcutaneous high concentration buprenorphine in rabbits has substantial pharmacokinetic variability and accumulation of both the parent drug and metabolites occurs with multiple dosing regimens. Subclinical illness may have impacted these findings and is a notable study limitation. Local inflammation in subcutaneous fat at injection sites was noted in rabbits administered HCB.

Lara A. Sypniewski, et al. “Pharmacokinetics, blood and urine profile effects, and injection site histopathology following three daily injections of subcutaneous high concentration buprenorphine in New Zealand white rabbits (Oryctolagus cuniculus).” Journal of Exotic Pet Medicine. Volume 43, October 2022, Pages 51-56.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

World Veterinary Dermatology Day

Like0
Dislike0

Artificial insemination market to grow to $3B by 2028

Like0
Dislike0

February is National Pet Dental Health Month

Like0
Dislike0

Falling markets? Don't panic, it's not the first time

Like0
Dislike0

Treatment of canine chronic cutaneous lupus erythematosus with oclacitinib

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2023 - All Rights Reserved
ISSN 2768-198X

Top